# Envarsus XL Immunosuppression Following Liver Transplantation

> **NCT03828058** · PHASE2 · COMPLETED · sponsor: **Methodist Healthcare** · enrollment: 110 (actual)

## Conditions studied

- Recipients of Liver Transplant

## Interventions

- **DRUG:** Envarsus XR
- **DRUG:** Prograf

## Key facts

- **NCT ID:** NCT03828058
- **Lead sponsor:** Methodist Healthcare
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-01
- **Primary completion:** 2020-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2021-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03828058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03828058, "Envarsus XL Immunosuppression Following Liver Transplantation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03828058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*